For instance, two small molecule HIF-2α inhibitors, MD6482 (also known as PT2977) and PT2385, exhibited promising activities in experimental models, and based on the results of clinical testing in participants with advanced renal cell carcinoma, MK6482 became the first FDA-approved HIF-2α inhibitor (1). The gene discussed is EPAS1; the disease is hereditary clear cell renal cell carcinoma.